The reclassification of obesity as a disease has fundamentally reshaped the pharmaceutical industry’s approach to weight management, with profound implications for how treatments are developed, marketed, and accessed. Max Moser’s analysis in STAT News draws parallels between the current obesity pharmacotherapy boom and the antidepressant revolution, questioning who stands to benefit most from disease framing in medicine.
Key takeaways
- Disease classification of obesity has accelerated pharmaceutical development of GLP-1 receptor agonists and similar agents
- The framing mirrors historical patterns in psychiatry, where disease classification expanded both treatment access and commercial markets
- Financial incentives shape how obesity is defined and treated, raising questions about equity and appropriate use
- Disease status enables insurance coverage and reimbursement pathways that were previously unavailable
The disease framing precedent: lessons from psychiatry
Max Moser, writing in STAT News, draws an explicit historical parallel to the antidepressant revolution of the 1990s and 2000s. When major depressive disorder became formally recognised as a disease requiring medical intervention, pharmaceutical companies substantially expanded treatment development and marketing, transforming psychiatry’s therapeutic landscape. Moser argues that the current obesity treatment expansion follows a similar trajectory: disease classification legitimises pharmaceutical intervention, creates reimbursement pathways, and generates substantial commercial opportunity.
This pattern is not unique to mental health. Clinical Updates across multiple therapeutic areas show that disease designation consistently precedes market expansion. The question Moser raises is whether the benefits of treatment access equitably distribute across populations, or whether pharmaceutical profitability drives classification decisions.
Market expansion following disease classification
Comparative timeline: disease recognition, treatment development, and market growth
Source: Comparative pharmaceutical market analysis, STAT News analysis | Georgian Medical Journal News
Financial incentives and pharmaceutical development priorities
Moser’s central argument hinges on a critical observation: once obesity achieves formal disease status, pharmaceutical companies face powerful incentives to develop and market treatments. Insurance reimbursement becomes possible, patient populations expand, and the addressable market grows substantially. Major companies including Eli Lilly and Novo Nordisk have invested billions in GLP-1 receptor agonist development, driven partly by the disease framing that legitimises these agents as medical necessities rather than elective interventions.
The mechanism is economically rational: disease classification removes ambiguity about whether treatment is medically justified, simplifies reimbursement approval, and allows pharmaceutical companies to charge premium prices justified by medical benefit claims. Yet this creates a tension. As Health Policy researchers have documented, disease definitions are not immutable—they evolve as medical understanding improves, but also as commercial interests shift. Moser’s analysis suggests the current obesity classification reflects both genuine medical evidence and powerful economic incentives aligned in the same direction.
Who benefits? Access versus profitability
Moser does not argue that obesity treatment is without merit. Rather, he questions whether disease framing inevitably benefits patients equitably or whether it primarily serves industry interests. GLP-1 agents such as semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) have demonstrated genuine clinical efficacy in multiple clinical trials, supporting their use in appropriate populations. Disease classification has enabled insurance coverage that makes these treatments accessible to patients who could not previously afford them.
However, the same classification framework that expands access also expands markets, enabling pharmaceutical companies to pursue aggressive pricing and marketing strategies. In countries with weak healthcare regulation, disease framing can drive overtreatment, inappropriate prescribing, and financial burden on healthcare systems. This raises a foundational question that Moser leaves deliberately open: who ultimately benefits—patients seeking effective treatment, or companies maximising shareholder returns?
The reclassification of obesity as a disease has followed a pattern established in psychiatry: disease designation accelerates pharmaceutical development, enables insurance reimbursement, and creates substantial commercial opportunity—benefits that do not necessarily distribute equitably across all patient populations.
— Max Moser, analysis in STAT News
Clinical and policy implications going forward
Moser’s commentary carries important implications for clinicians and policymakers evaluating obesity treatment frameworks. On one hand, disease status legitimises medical intervention, funds research, and expands access for patients who benefit from pharmacotherapy. On the other hand, it creates economic incentives that may drive overdiagnosis, overselling of marginal benefits, or inappropriate use in low-risk populations.
The parallel to antidepressants is instructive: those agents offer genuine benefit for moderate to severe depression, yet disease framing also contributed to widespread prescribing in milder conditions where evidence is weaker. Similar dynamics could emerge in obesity treatment if disease classification is decoupled from careful patient selection and individualized risk-benefit assessment. Policymakers designing obesity care systems should consider whether funding and reimbursement frameworks incentivise appropriate use or merely expand pharmaceutical markets at public expense.
What this means
Frequently asked questions
Is obesity genuinely a disease?
Yes, obesity meets standard disease criteria: it involves pathological dysfunction, carries health risks including cardiovascular and metabolic complications, and benefits from medical intervention in appropriate populations. However, the framing as disease, while medically justified, also creates commercial incentives that shape how the condition is diagnosed and treated. Disease status and profit motive can coexist without negating the medical reality.
Why does disease classification matter financially?
Disease classification enables insurance reimbursement, regulatory approval pathways, and public health coverage that would not apply to non-disease conditions. This dramatically expands the addressable market for pharmaceutical treatments and justifies premium pricing. Manufacturers of GLP-1 agents have invested billions in development partly because disease status guarantees reimbursement and market access that would be unavailable for weight loss agents marketed purely as lifestyle or cosmetic treatments.
Could obesity be overtreated if disease framing creates financial incentives?
Yes, history suggests this risk is real. The antidepressant revolution expanded treatment access for genuine depression but also drove substantial prescribing in mild or subsyndromal cases where evidence of benefit is weaker. Similar dynamics could emerge in obesity if disease classification becomes decoupled from careful patient selection and clinical judgment, potentially leading to inappropriate prescribing in low-risk populations or overreliance on pharmaceutical solutions.
Max Moser’s analysis does not offer a definitive answer to whether obesity disease classification represents genuine medical progress or pharmaceutical opportunism—likely because the truth reflects both. The critical task for clinicians, policymakers, and patients is maintaining healthy scepticism about financial incentives while remaining open to evidence-based treatment. The obesity pharmacotherapy boom offers real benefits to appropriately selected patients; the challenge is ensuring that benefits are distributed equitably and not obscured by commercial interest.
Source: Opinion: Who benefits from classifying obesity as a disease? STAT News
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
